Estimated reading time: 2 minutes
The SOLIS trial was presented at the North American Neuromodulation Society Meeting in Las Vegas recently. It showcased promising results for Boston Scientific's WaveWriter Alpha Spinal Cord Stimulation (SCS) system in alleviating chronic pain. The one-year data revealed a significant 50% reduction in patient pain, marking a substantial advancement in pain management. The study indicated that 85% of patients who reported a decrease in pain also experienced enhanced participation in daily activities. This was coupled with a notable 25-point improvement in disability, as measured by the Oswestry Disability Index.
Outcomes and Results
Jim Cassidy, President of Neuromodulation at Boston Scientific, emphasized the significance of these positive outcomes from the SOLIS study. The findings underscore the importance of early and effective pain treatment, especially when conventional standards of care fall short. The SCS system by Boston Scientific has consistently demonstrated solutions for pain management. The hope is it could improve the quality of life for any patient grappling with chronic pain.
The study adds to the growing body of evidence supporting the efficacy of Boston Scientific's SCS system. Other studies, including the Global, multicenter study for Painful-Diabetic Peripheral Neuropathy and the FAST Therapy study, have also reported favorable results. In these studies, a significant percentage of patients experienced a 50% or greater reduction in pain. This showcases the versatility and potential impact of Boston Scientific's neurostimulation technology.
Boston Scientific
As the field of neurostimulation evolves, Boston Scientific remains a key player. They are engaging in efforts to expand its pain mitigation portfolio. The acquisition of Relievant Medsystems for an upfront cash payment of $850 million further exemplifies the company's commitment to advancing innovative solutions in pain management. With a competitive market featuring numerous spinal cord stimulator devices in development, Boston Scientific's continued positive results position it as a leading player in the field, vying for prominence alongside its US-based competitor, Medtronic.
Looking for ways to manage your chronic pain? PatientsLikeMe is a health platform dedicated towards creating meaningful change in people's lives. We have dedicated resources and tools to help you in your journey. Creating an account is free! Join today.